Pfizer’s skin disease drug meets main goal in late-stage trial

(Reuters) – Pfizer Inc said on Monday its drug to treat patients with moderate to severe atopic dermatitis met main goal in a late-stage study and was statistically superior compared to rival from Regeneron.

(Reporting by Dania Nadeem in Bengaluru)